PCT

(30) Priority data:

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:
A61F 2/06
A1 (11) International Publication Number: WO 92/03107
(43) International Publication Date: 5 March 1992 (05.03.92)

(21) International Application Number: PCT/US91/05907

(22) International Filing Date: 27 August 1991 (27.08.91)

573,932 28 August 1990 (28.08.90) US

(71) Applicant: MEADOX MEDICALS, INC. [US/US]; 112 Bauer Drive, Oakland, NJ 07436 (US).

(72) Inventor: SCHMITT, Peter, J.; 2 Bubenko Drive, Garnerville, NY 10923 (US).


(74) Agents: WOLFSON, Michael, I. et al.; Blum Kaplan, 1120 Avenue of the Americas, New York, NY 10036 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), IP, LU (European patent), NL (European patent), SE (European patent).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: SELF-SUPPORTING WOVEN VASCULAR GRAFT



(57) Abstract

A woven synthetic fabric tubular vascular graft including a stiffening component in the filling yarn which is self supporting without crimping the walls of the graft. The graft is woven from warp ends of multifilament polyester yarns and elastomeric yarns and a filling yarn which includes multifilament and monofilament polyester yarns which have been twisted together. Longitudinal and radial compliance provides for improved kink resistance making the tubular grafts suitable for use in medium and small diameter peripheral applications. A preferred graft has a velour outer surface and a smooth inner surface.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Snain	MG	Madagascar
AU	Australia	ΡI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinca	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic	SE	Sweden
CH	Switzerland		of Korea	SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	su+	Soviet Union
CM	Cameroon	Li	Liechtenstein	TD	Chad
cs	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE*	Germany	LU	Luxembourg	US	United States of America
UK	Dunmack	MC	Monago		

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

SELF-SUPPORTING WOVEN VASCULAR GRAFT

BACKGROUND OF THE INVENTION

This invention relates to synthetic vascular grafts, and more particularly to synthetic woven vascular grafts including a stiffening component to provide a non-crimped self-supporting graft.

Vascular grafts of synthetic materials are widely used for the replacement of segments of human blood vessels. Synthetic vascular grafts have taken a wide variety of configurations and are formed of a wide variety of materials. Among the accepted and successful vascular graft implants are . those formed from a biologically compatible material in tubular form which retain an open lumen to permit blood to flow normally through the graft after implantation. The compatible materials biologically include thermoplastic materials such as polyester, polytetrafluoroethylene (PTFE), silicone and polyurethanes. The most widely used are polyester fibers and PTFE. The polyester fibers, usually Dacron, may be knit or woven and may be of a monofilament, multifilament or staple yarn, or combination of each.

There are a wide variety of synthetic vascular grafts presently in use. An important factor in the selection of a particular graft is the porosity of the substrate of which the graft is formed, the resiliency of the tubular construction and the strength requirements for the implant. Porosity is significant, because it controls the tendency to hemorrhage during and after implantation and influences ingrowth of tissue into the wall of the graft.

Synthetic fabric vascular grafts may be of a woven, knitted with or without a velour construction. A synthetic vascular graft having a warp-knit construction is disclosed by William J. Liebig in U.S. Patent No. 3,945,052. Another graft having a warp knit double-velour construction is described by Liebig and German Rodriquez in U.S. Patent No. 4,047,252. William J. Liebig and Dennis Cummings describe a synthetic woven double-velour graft in U.S. Patent No. 4,517,687; the velour loops being formed of warp yarns which are texturized preshrunk multifilament yarns. These three issued United

S. Polansky in U.S. Patent No. 3,304,557 avoids crimping in vascular prothesis by forming a tube with repeating reinforcing ring sections. These reinforcing ring sections incorporate reinforcing picks adjacent only the outer surface. He proposes that the annular rings can be in the form of a helix, alternating rings and helix-loops. These latter suggestions are similar to the tubular prosthesis of I. B. Medell in U.S. Patent No. 3,479,670 wherein an open mesh tube is wrapped with two polypropylene monofilament right-hand and left-hand helices and fused to penetrate partially the exterior of the tube. In U.S. Patent No. 3,272,204 to C. Artandi and L. D. Bechtol sew a Dacron fabric to Teflon rings or a helix to prevent an absorbable collagen reinforced graft tube from collapsing.

Selection of a particular type of graft substrate by a vascular surgeon depends upon several factors. Among the included is factors the particular location of implantation. This also dictates the size of the graft in order to maintain a sufficiently large or small lumen to accommodate normal blood flow in the region of implantation. The ultimate strength requirements and blood pressure in the location of implantation also affect the selection. Generally, the woven grafts provide greater strength and reduced porosity, but are generally considered to be more difficult to handle and Velours are often preferred because the velour surfaces facilitate growth of tissue into the loops extending from the surface of the velour fabric. The knitted grafts are generally softer and more easily sutured, but are generally Depending on the location of the implant and more porous. heparinization condition of the patient, synthetic fabric grafts generally must be preclotted with the patients blood before implantation. Preclotting may not be essential with a woven graft, but is generally recommended nonetheless.

Tubular grafts of smaller diameter, for example, 6 mm and below are often utilized in peripheral regions of the body and appendages. Today, the most successful in this respect are grafts of PTFE of the material disclosed by Robert W. Gore in

4

U.S. Patents Nos. 4,187,390 and No. 3,953,566. These grafts are formed by extrusion of the PTFE material. While accepted for use in small diameter applications, PTFE grafts often require surgical replacement within relatively short periods of time compared to the larger diameter fabric vascular grafts described above.

Accordingly, it is desirable to provide a synthetic fabric vascular graft suitable for a wide variety of dimensions and diameters providing the benefits of woven grafts, but which do not require crimping and will be self supporting and maintain an open lumen.

SUMMARY OF THE INVENTION

Generally speaking, in accordance with the invention, self-supporting a woven synthetic vascular grafts having improved kink resistance including a stiffening component in the filling yarn is provided. The stiffening component of the filling yarn provides radial burst strength, dimensional stability and radial rigidity with resiliency to maintain the lumen of the tubular structure open and provide the necessary burst strength properties. The graft may also include low modulus elastomeric warp yarns. In one preferred embodiment, a plurality of elastomeric and multifilament warp yarns are woven in tubular form with a filling yarn of stiffer monofilament and multifilament yarn which have been twisted The elastomeric warp yarns provide longitudinal compliance (stretch) which aids in bending flexibility. graft surfaces may be smooth or as a single or as a double velour.

In a single velour self-supporting vascular graft, the inner surface is provided with a fine, low profile woven surface to promote smooth, thin pseudointima formation. The loops on the exterior surface are formed of multifilament warp yarns which provide the necessary texture cover for tissue adhesion and ingrowth. The multifilament warp yarns and the multifilament component of the filling yarns control blood porosity. The filling yarn is a monofilament yarn twisted with

a multifilament yarn to provide required strength and reduce porosity.

The self-supporting woven grafts prepared in accordance with the invention are particularly well suited to 2-6 mm diameter peripheral vascular prosthesis, but are suitable for larger dimensions up to about 40 mm as well. Kink resistance is provided without the necessity to crimp the vascular graft.

Accordingly, it is an object of the invention to provide an improved woven synthetic vascular graft.

Another object of the invention is to provide a self-supporting woven synthetic vascular graft which resists kinking without the need to crimp the graft.

A further object of the invention is to provide a woven synthetic fabric vascular graft which is suitable for peripheral use in small diameters of 6 mm or less.

Still another object of the invention is to provide a small diameter woven synthetic fabric vascular graft which resists kinking and provides a desirable amount of longitudinal stretch without crimping.

Still a further object of the invention is to provide a self-supporting woven synthetic fabric vascular graft which includes an outer velour surface to promote tissue ingrowth.

Yet another object of the invention is to provide a self-supporting woven synthetic vascular graft having a fine, low profile woven surface to promote smooth, thin pseudointima formation.

Yet a further object of the invention is to provide a self-supporting woven synthetic fabric single-velour vascular graft having improved kink resistance without crimping.

Another object of the invention is to provide a method of preparing an improved self-supporting woven synthetic fabric vascular graft in accordance with the invention.

Still other objects and advantages of the invention will in part be obvious and will in part be apparent from the specification.

6

The invention accordingly comprises the several steps and the relation of one or more of such steps with respect to each of the others, the apparatus embodying features of construction, combination and arrangement of parts which are adapted to effect such steps, and the product which possesses the characteristics, properties, and relation of constituents (components), all as exemplified in the detailed disclosure hereinafter set forth, and the scope of the invention will be indicated in the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

For a fuller understanding of the invention, reference is had to the following description taken in connection with the accompanying drawings, in which:

FIG. 1 is a weaving diagram of a woven synthetic fabric vascular graft prepared in accordance with a preferred embodiment of the invention;

FIG. 2 is a cross-sectional view in schematic in the warp direction of a finished graft section showing the interlacing ends of filling yarn of a graft fabric having the weave pattern of FIG. 1;

FIG. 3 is a perspective view of a tubular woven single-velour vascular graft prepared in accordance with the invention; and

FIG. 4 is a perspective view of a bifurcated woven single-velour vascular graft prepared in accordance with the invention.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The woven tubular synthetic vascular grafts prepared in accordance with the invention are applicable to a wide range of diameters, including the small 2 to 6 mm diameter range suitable for peripheral use as well as dimensions up to about 40 mm. Accordingly, the grafts woven having inside diameters which range from about 2 to about 40 mm and are self-supporting and resist kinking without being crimped.

The stiffening component in the filling yarns may be a textile material, such as a monofilament yarn. Selection

will vary depending on the desired characteristic of the tubular graft. However, the stiffening component must be sufficiently stiff to impart dimensional stability and radial rigidity to the tube without crimping. The stiffening component should have the following minimum physical properties:

Tenacity: ≥ 3 grams per denier

(53,000 psi)

EI: $\geq 3.9 \times 10^{-8} lb.in.^2$

Where EI is the bending stiffness, E is the initial modulus of elasticity and I is the moment of inertia. The diameter can vary depending on desired characteristics, but will typically be in the range of about 2 to 10 mils.

In one preferred embodiment of the invention, the woven graft has a diameter less than about 6 mm. In another preferred embodiment the woven graft has an exterior surface with loops and a smooth interior surface. The grafts are self-supporting and resistant to kinking without crimping the fabric surface. The grafts possess longitudinal elasticity imparted by including a plurality of thermoplastic low modulus elastomeric yarns as a component of the warp yarns. Elastomeric Yarns have properties which exhibit high stretch, low modulus, and good elastic recovery. Typical properties for yarns suitable for use would be:

Elongation to Break: >100%

Modulus of Elasticity: <1 gram per denier

Elastic Recovery: >80%

or

Tensile Set: <20%

The resin can either be thermoplastic or thermoset, but should possess good biocompatibility. The remaining yarns utilized are those which are compatible biologically. Such yarns include polyethylene terephthalate, polyurethane, polytetrafluoroethylene and silicone.

8

Preferably, the majority of the yarn utilized in the woven graft is polyethylene terephthalate, such as Dacron available from du Pont. The remaining component is the elastomeric yarn which may be present in amounts ranging from about 2 to 20 percent by weight. The graft substrate is formed by weaving a plurality of warp yarns including elastomeric yarn and multifilament yarn with filling yarns of stiffer monofilament yarn and multifilament yarn which have been twisted together prior to weaving. The stiffer monofilament component of the filling yarn provides mechanical strength, dimensional stability and radial rigidity with resiliency which maintains an open lumen for normal blood flow and provides the necessary burst strength. The elastomeric warp yarn component provides longitudinal compliance which aids in bending flexibility.

The monofilament polyester utilized as a stiffening component in the Examples which follow is a 5 mil polyethylene terephthalate yarn. The yarn has the following physical properties:

Diameter: .005 inch (5 mils or 0.127 mm)

Tenacity: 6.2 grams per denier

(110,000 psi)

Initial Modulus: 112 grams per denier

(1,980,000 psi)

I (moment of inertia) = $\frac{\pi r^4}{64}$

Calculated Bending Stiffness = $E \times I$

 $EI = 3.8 \times 10^{-6} \text{ lb.in.}^2$

The multifilament warp yarns and multifilament component of the filling yarns provide the necessary texture and cover for tissue adhesion and ingrowth on the outer surface and assist in controlling porosity of the graft. The velour loops are of multifilament warp yarns on the outer surface only. The inner surface has a fine, low profile which promotes smooth, thin pseudointima formation.

9

The particular selection of elastomeric and multifilament warp yarns together with the stiffer combined monofilament and multifilament filling yarns provide a graft having improved kink resistance over a wide range of diameters. Thus, smaller bending radii can be achieved without occluding. In the preferred single velour construction, the external velour surface promotes tissue ingrowth.

FIG. 1 illustrates the weaving pattern of a woven vascular graft substrate 11 prepared in accordance with a preferred embodiment of the invention. Substrate 11 is woven from a plurality of warp ends 12 and filling yarn 13. FIG. 2 is a schematic illustration at substrate 11 in cross-section with a smooth interior surface 14 and a velour exterior surface 16 having loops 17 of multifilament warp yarns 19 which stand away from the surface of the graft.

Referring to FIG. 1, warp yarns 12 include alternating ground warp ends of a first multifilament yarn 18 and, a low modulus elastomeric monofilament yarn 19. illustrated embodiment multifilament yarn 18 is a one ply seventy denier untexturized preshrunk (flat) polyethylene terephthalate (Dacron) yarn (1/70/54) with a 5z twist (one ply/70 denier 54 filaments). Elastomeric yarn 19 is a 140 denier polyurethane (Lycra Spandex) or an S-E-B-S (styreneethylene-butylene-styrene block copolymer). Two ends of multifilament ground warp yarn 18 alternate with one end of ground warp elastomeric yarn 19. The loop or pile component 19 of warp yarns 12 is a multifilament warp yarn 21 which alternates with each end of warp ground yarns 18 and 19. substrate 11, multifilament yarn 21 is an texturized unshrunk 2/40/27 (two ply/40 denier (27 filament) with a 1.55 twist) polyethylene terephthalate (Dacron) yarn.

Filling yarn 13 is a combined yarn of a monofilament yarn component 22 twisted together with a multifilament yarn component 23 to form filling yarn 13. In substrate 11, monofilament yarn 12 is a 5 mil polyethylene terephthalate monofilament yarn twisted with multifilament yarn component 23 which is a texturized preshrunk yarn 2/40/27 (1.5s). This is

the same yarn as texturized preshrunk warp direction yarn 21. The components are twisted 1.5 turns per inch in the "5".

Elastomeric component 19 of warp yarns 12 may be formed of any one of the biologically compatible materials having a low modulus of elasticity as noted above. The modulus of elasticity is typically less than 1 gram per denier with an elongation to break greater than 100 percent. For example, the elastic component may be a polyester, polyurethane, silicone or other compatible copolymers such as a styrene-ethylenebutylene-styrene block copolymer known as a C-Flex resin available from Concept Polymers. The elastomeric component is present in substrate 11 in an amount between about 2-20 percent by weight. Preferably, elastomeric component 19 is present in an amount about 5 to 10 percent by weight. The styreneethylene-butylene-styrene block copolymer monofilament yarn is 5 mil C-Flex. An alternative preferred yarn suitable for elastomeric component 19 is a Lycra polyurethane yarn of 140 denier.

FIG. 3 is a perspective view of a tubular graft 31 prepared in accordance with the invention. Graft 31 has a smooth inner surface 32 and external raised fabric velour surface 33 having a multiplicity of outwardly extending loops 34. Similarly, FIG. 4 illustrates a bifurcated graft 41 having a main body segment 42 and two legs 43 and 44. Legs 43 and 44 are joined to main body 42 at a crotch 46 which is generally reinforced by a row of stitches 47 to maintain as tight an initial porosity of the graft as possible. Graft 41 has a smooth interior surface 48 and an external surface 49 having loops 51.

As is evident from the weaving pattern of FIG. 1, loops 34 and 51 of grafts 31 and 41, respectively are formed from multifilament warp pile yarns. In substrate 11 the pile yarns are texturized unshrunk polyester yarns 21.

After weaving substrate 11 in the pattern as shown in FIG. 1, grafts 31 and 41 are scoured and washed in a hot water and detergent bath which results in about 10 to 30 percent longitudinal shrinkage. The washed tubes are cut to desired

ħ

lengths and heatset in a convection oven on straight aluminum mandrels at about 175°C for about 15 minutes to one hour. The grafts can also be heat set in a non-straight condition to create shaped grafts, such as an aortic arch, which will not have to be bent or shaped by the surgeon during implantation.

As discussed above, and as shown in FIGS. 3 and 4, tubular woven vascular grafts 31 and 41 prepared in accordance with the invention are not crimped in order to maintain an open lumen. This is due to inclusion of the relatively stiffer monofilament component 22 in filling yarns 13 and elastomeric component 19 in warp yarns 12.

The specifications of the yarn utilized and substrate 11 are set forth in the following Examples. These Examples are presented for purposes of illustration and are not intended in a limiting sense.

Example 1

Tubular grafts were woven with the following yarns on the pattern of FIG. 1.

TUBULAR WEAVE CONSTRUCTION:

Ground weave for lattice structure: plain
Warp float weave for loop or pile surface:
Crowfoot (floats on outside surfaces, See FIG.
2) alternates every other end (See FIG. 1)

YARN CONSTRUCTION:

Warp Ground: 1/70/54 (5z) Untexturized Preshrunk

Dacron 56 Polyester & 5 mil C-Flex, alternating 2 ends of Dacron 56

Polyester and 1 end of C-Flex.

Warp Float: 2/40/27 Texturized Unshrunk Dacron 56

Polyester (1.5s).

Filling: 5 mil PET Monofilament wound together

with 2/40/27 Preshrunk Texturized

Dacron (1.5s).

12

DENSITY DESCRIPTION:

Sley: 320 ends per inch (40 dents/inch x 8

ends/dent)

Picks: 60 picks per inch per layer (120 total)

TUBE DESCRIPTION:

Greige Inside Diameters: 4.5, 5.5 & 6.5 mm Finished Inside Diameters: 4, 5 & 6 mm

Example 2

In another preferred embodiment in accordance with the invention a 140 Denier Lycra Spandex monofilament yarn is utilized as the elastomeric component 19 in the same pattern as substrate 11. Tubular vascular grafts having an identical weaving pattern as shown in FIG. 1 are formed with the following specifications:

TUBULAR WEAVE CONSTRUCTION:

Ground weave for lattice structure:

plain

Warp float weave for loop or pile surface:

crowfoot (floats on outside surface, See FIG. 2) weave alternates on every other

end (See FIG. 1)

YARN CONSTRUCTION:

Warp Ground: 1/70/54 (5z) untexturized unshrunk

> Dacron 56 polyester and 140 Denier Lycra monofilament, alternating 2 ends of polyester and 1 end of Lycra.

Warp Float: 2/40/27 (1.5s) - Dacron 56 Texturized

Preshrunk Polyester.

Filling: 5 mil PET Monofilament wound together

> with 2/40/27 preshrunk textured

Dacron 56 polyester.

DENSITY DESCRIPTION

Sley: 320 epi (40 dents/inch x 8 ends/dent)

Picks: 60 picks per inch inserted per layer

in tubular form.

13

TUBE DESCRIPTION:

Greige Inside Diameter:

8 mm

Finished Inside Diameter:

4.8 mm

The velour for both grafts was formed by weaving every other end in a crowfoot pattern, which allows the warp yarn to float over three picks and under one pick. The remaining adjacent ends form a plain weave. Every third warp end in the lattice structure is Lycra or C-Flex, which in total means that one in six warp ends is elastomeric yarn. The elastomeric yarn causes the fabric to retract in length which raises the floats of the warp weaving in a crowfoot pattern to form loops.

After weaving, the self-supporting woven single velour graft material of Example 2 was scoured and dried and then rinsed to remove trace chemicals and dried again. Scouring shrank or relaxed the graft tubing about 20.5%. The relaxation which occurs contributes to the ultimate longitudinal stretch.

The tubing was pressed along the tubing edges to remove the crease line formed during weaving. The tubing was then cut to 36 cm lengths and heatset by sliding them onto straight aluminum mandrels at the cut length and placed into a convection oven at 121°C for 20 minutes.

The Dimensional changes before and after finishing were as follows:

Property	Example 2
Longitudinal Shrinkage from greige to scoured, %	20.5
Longitudinal Shrinkage from scoured to heatset, %	11.3
Total longitudinal shrinkage from greige to heatset, %	29.5
Fabric count after weaving, epi x ppi	192±0 X 70.5±2.2

14

Fabric count after scouring, epi x ppi

192±0 X 88.7±1

Fabric count after heat setting, epi x ppi

192±0 X 100±1

3

The porosity of the grafts was measured using a Wesolowski permeability tester. Six specimens were tested at two locations. The paired values were added together and reported as a single value. The grafts were tested both relaxed and stretched using a 4 lb weight. The results were as follows:

Permeability (ml/min/cm²)

<u>Graft</u>	Relaxed	<u>Stretched</u>
WSV (Lycra)	1004±96	1284±124

The average burst strength of the graft was determined by measuring six graft samples on an Instron Tensile Tester and was 509 ± 58 psi.

A woven single velour graft woven with Lycra Spandex [WSV (Lycra)] was tested for the force required to pull a suture from the end of the graft. One 2-0 Dexon suture was inserted through the graft 3 mm from the edge. The graft was mounted in the bottom pneumatic grip of the Instron Tensile Tester and the suture in the top grip. The tensile tester was activated to cause the suture to be torn from the graft. The graft exhibited a suture pullout of 7.50±.3 kg for a cut edge and 7.66±.21 kg for cauterized specimens.

Observations of the failed specimens disclosed that the cut edge grafts had an elongated hole before the filling yarns ruptured. The cauterized grafts had a more circular hole before rupture. This suggests that cauterizing the graft end is preferable to minimize distortion of the suture hole as well as prevent unravelling of the yarns during handling.

<u>Thickness</u>

The graft wall thickness and pile height was determined using SEM analysis. The average overall wall thickness was 0.80 mm with a pile height of 0.48 mm.

15

Longitudinal Compliance

The longitudinal compliance is a relative measurement of the ability of the graft to elongate at a given force and is expressed as the percent elongation per kilogram force. The longitudinal compliance was measured on an Instron Tensile Tester using pneumatic grips as follows.

The Instron was set to the following settings:

Full Scale Load: 2 kg

Crosshead Speed: 10 in/min
Chart Speed: 10 in/min

Gauge Length: 3 in

Load Cycling Limits: 0.1 kg to 1.0 kg

The specimens were mounted in the grips with a preload tension of 0.04 kg. The specimens were cycled between 0.1 and 1.0 kg for a total of 50 cycles. On the 50th cycle, the strip chart recorder was activated to record the event. After the last cycle, the crosshead was returned to the 0.1 kg force and stopped. The extension indicated on the digital readout was recorded. This value was added to the original gauge length of 3 inches to arrive at the effective gauge length for calculating the percent elongation and compliance. The average longitudinal compliance was 23.4 %/kg.

Kink Resistance

The relative kink resistance was measured in a dry, non-pressurized condition. This was a quick test to see if the graft could be bent longitudinally without kinking. If or when it did kink, to what extent, as determined by the inside radius of curvature.

Four graft specimens, 15 to 20 cm in length, were looped in a circular fashion such that the ends were facing in opposite directions. The ends were slowly and gently pulled so as to reduce the diameter of the loop. The ends were pulled until the first evidence of kinking occurred in the wall of the grafts. This procedure took place on the surface of a metric ruler so that the inside diameter could be continuously monitored to capture the point of kinking.

E

The WSV (Lycra) grafts kinked at a diameter of 18±1.7 mm. If we divide the diameter by two to obtain the inside radius of curvature and then divide this by the inside graft diameter of 4.8 mm, we obtain a 1.9±.2 Rad./Graft Diameter value which can be used for comparing to other grafts.

These grafts prepared in accordance with the invention are considered kink resistant, since they are flexible longitudinally and can be looped or bent to a significant degree. Typically, rigid or non-longitudinally compliant grafts or tubular structures will kink immediately upon the application of sufficient stress to deform the structure about their longitudinal axis.

Radial Compression

Radial compression of the graft was measured to determine the crush resistance of the graft. Four specimens between 15 and 20 cm in length were individually mounted into an Instron Tensile Tester with a flat plate compression apparatus, which measured 4 inches in diameter. The specimens were mounted into the compression apparatus so that the ends of the grafts extended beyond the ends of the plates. The gap between the upper and lower plates was reduced so that they came into contact with the specimens and exerted a preloaded force of .02 kg. The distance between the plates was measured with a Vernier to the nearest 0.5 mm, which is the initial gap. The crosshead travel was started at a rate of 0.5 inches/min and stopped when the grafts were completely compressed.

The strip charts generated were analyzed by measuring the slope of the curves to determine the compression moduli. The compression modulus is calculated by the following formula:

Compression Modulus, $g/cm = \frac{Force, g \times Initial \ gap, mm}{Displacement, mm \times 4 \ in \times 2.54cm/in}$

In order to compare the values of two types of grafts with different diameters the modulus values can be normalized by multiplying them by the inside diameters of the graft. The

17

resulting units are grams - millimeter diameter per centimeter length.

The self-supporting WSV (Lycra) grafts exhibited a radial compression of 2850±182 g-mm/cm. The radial compression is an important property in contributing to the ability of a graft to resist kinking when deformed. If the radial compression is high with respect to longitudinal compliance or stiffness, then kink resistance is achieved. If radial compression is low, the wall of the graft is more flexible and consequently kinks more readily.

Graft substrate 11 in FIG. 1 includes every third ground warp end of elastomeric component 19 resulting in one in six warp ends being elastomeric component 19. Elastomeric component 19 causes substrate 11 to retract in length which raises the floats of the warp yarns to form loops in a crowfoot pattern to form loops 17. Filling yarn 13 includes texturized preshrunk polyester, but may be either texturized untexturized depending on the shrinkage characteristics The only requirement is that these yarns be multifilament to assist in reducing porosity of the graft and facilitating tissue adhesion and ingrowth after implantation. The stiff monofilament component of filling yarn 13 provides radial burst strength, dimensional stability and radial rigidity with resiliency to maintain an open lumen for normal blood flow and provide the necessary burst strength of the graft.

The characteristics and properties of the graft woven in accordance with the invention can be varied as desired by selection and combination of the starting warp and filling yarns and the weaving pattern. In the illustrated examples, the warp ground yarns are multifilament untexturized unshrunk (or flat) polyester, but could be texturized or untexturized preshrunk or unshrunk, or elastomeric yarns. The preferred loop yarn is a multifilament texturized polyester yarn, but could also be untexturized, preshrunk or unshrunk. The sole limiting feature is that there be sufficient multifilament yarns considering the desired end results. The filling yarn is

18

a composite monofilament twisted with a multifilament component of texturized preshrunk yarn.

•

It will thus be seen that the objects set forth above among those made apparent from the preceding description, are efficiently attained and, since certain changes may be made in the above article without departing from the spirit and scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described and all statements of the scope of the invention which, as a matter of language, might be said to fall therebetween.

CLAIMS

WHAT IS CLAIMED IS:

- 1. A non-crimped self-supporting tubular woven synthetic vascular graft having a continuous uniform surface, comprising:
- a filling yarn including a stiffening component to provide radial burst strength, dimensional stability and radial rigidity sufficient to maintain the lumen of the tubular structure open.
- 2. The woven synthetic vascular graft of claim 1, wherein the stiffening component is a textile yarn.
- 3. The woven synthetic vascular graft of claim 2, wherein the textile yarn is a monofilament yarn.
- 4. The woven synthetic vascular graft of claim 3, wherein the monofilament filling yarn is combined with multifilament yarns.
- 5. The woven synthetic vascular graft of claim 3, wherein the monofilament textile yarn is a polyethylene terephthalate yarn.
- 6. The woven synthetic vascular graft of claim 3, further including a plurality of warp ends including multifilament yarns.
- 7. The woven synthetic vascular graft of claim 6, wherein the warp ends include elastomeric yarns.
- 8. A self supporting tubular woven synthetic vascular graft, comprising:
- a plurality of warp ends including multifilament yarns; and
- a filling yarn including a monofilament component.
- 9. The woven vascular graft of claim 8, wherein the multifilament yarns are polyethylene terephthalate.
- 10. The woven vascular graft of claim 8, wherein the monofilament component is a polyethylene terephthalate yarn.
- 11. The woven vascular graft of claim 8, wherein the filling yarn includes monofilament yarn twisted together with multifilament yarn.

\$

۶

ŗ

- 12. The woven vascular graft of claim 11, wherein the multifilament component of the filling yarn is polyethylene terephthalate yarn.
- 13. The woven vascular graft of claim 12, wherein the multifilament and monofilament components of the filling yarn are polyethylene terephthalate.
- 14. The woven vascular graft of claim 13, wherein the monofilament component of the filling yarn is polyethylene terephthalate wound together with preshrunk, texturized multifilament polyethylene terephthalate.
- 15. The woven vascular graft of claim 14, wherein the multifilament yarn of the warp is preshrunk.
- 16. The woven vascular graft of claim 15, wherein the preshrunk yarn is polyethylene terephthalate.
- 17. The woven vascular graft of claim 8, including a plurality of warp ends of an elastomeric yarn.
- 18. The woven vascular graft of claim 17, wherein the elastomeric yarn is a polyurethane.
- 19. The woven vascular graft of claim 17, wherein the elastomeric yarn is a styrene-ethylene-butylene-styrene block copolymer.
- 20. The woven vascular graft of claim 8, wherein the multifilament warp yarns include preshrunk texturized and unshrunk untexturized polyethylene terephthalate yarn.
- 21. The woven vascular graft of claim 8, wherein the multifilament warp yarns include preshrunk texturized and unshrunk texturized polyethylene terephthalate yarn.
- 22. The woven vascular graft of claim 8, wherein the warp ends include a plurality of elastomeric yarns, and the elastomeric yarn alternates with the multifilament yarn.
- 23. The woven vascular graft of claim 22, wherein two ends of multifilament yarn alternate with one end of elastomeric yarn.
- 24. The woven vascular graft of claim 8, wherein the graft has at least one velour surface of a plurality of warp pile ends of multifilament yarn.

- 25. The woven vascular graft of claim 24, wherein the warp pile end alternates between each warp ground ends.
- 26. The woven vascular graft of claim 25, wherein the vascular graft is a tube with a single outside velour surface and a smooth interior surface, the velour surface formed from warp pile yarns of unshrunk texturized multifilament yarn.
- 27. The woven vascular graft of claim 26, wherein the warp pile yarn is unshrunk texturized polyethylene terephthalate.
- 28. The woven vascular graft of claim 1, wherein the filling yarn includes a monofilament having a diameter from about 2 to 10 mils.
- 29. A self-supporting tubular single velour woven synthetic vascular graft, comprising:
- a plurality of warp ground ends including multifilament yarn and elastomeric yarn;
- a plurality of warp pile ends of multifilament yarn; and

monofilament filling yarn.

- 30. The woven vascular graft of claim 29, wherein the filling yarn is a monofilament yarn wound together with multifilament yarn.
- 31. The woven vascular graft of claim 29, wherein the filling yarn is monofilament polyethylene terephthalate wound together with preshrunk texturized multifilament polyethylene terephthalate yarns.
- 32. The woven vascular graft of claim 31, wherein the warp ground ends are alternating preshrunk untexturized multifilament polyethylene terephthalate yarns and elastomeric yarns.
- 33. The woven vascular graft of claim 32, wherein the vascular graft is a tube with a single outside velour surface and a smooth interior surface, the velour surface formed from warp pile ends of unshrunk texturized multifilament polyethylene terephthalate yarn.

34. The woven vascular graft of claim 8, wherein the ends of the tube have been cauterized.

35. The woven vascular graft of claim 8, wherein the tubular graft is bifurcated having a main body portion and two branches.

ţ


۶

- 36. The woven vascular graft of claim 8, wherein the graft has a circular cross-section and is straight longitudinally.
- 37. The woven vascular graft of claim 8, wherein the graft has a circular cross-section and is curved along its length.
- 38. A process of preparing a self-supporting woven vascular graft, comprising:

weaving a tube of a plurality of warp ends including multifilament yarns with a monofilament fill yarn;

scouring said woven tube; and heat setting the fabric.

- 39. The process of claim 38, including weaving the tube with warp ends of elastomeric yarn.
- 40. The process of claim 38, wherein heat setting is carried out by placing the tube on a straight mandrel and heating to set the tube to a round cross-section and longitudinally straight shape.
- 41. The process of claim 38, where the heat setting is carried out by placing the tube on a curved mandrel, applying heat to set the tube into a the shape of the mandrel.



PERSONAL CONTROL

International Applicat Vo

GB, A, 820 014 (DAVENPORT) 16 September 1959 1-4 34- 38, see the whole document A US, A, 3 304 557 (POLANSKY) 21 February 1967 cited in the application A EP, A, 0 122 744 (HOWMEDICA) 24 October 1984 A WO, A, 8 303 752 (WALLSTEN) 10 November 1983 A US, A, 4 517 687 (MEADOX MEDICALS) 21 May 1985 cited in the application "A" document defining the general state of the art which is not considered to be of particular relevance filling data "I" document which say throw doubts on priority claims(s) or whigh is cited to establish the publication state of another citation or other peach in exact (see pacified) "O" document referring to an oral disclosure, usa, exhibition or other means "P" document published prior to the international filling date but late that the priority data can be considered in throw an inventive step with the considered in the consideration of the consideration or other peach in execution." "I document published prior to the international filling date but late that the priority data can be considered in over or annot be considered in the publication of the consideration of the consideration of the same publication of the international Search Report				S SEARCHED	IL FIELDS S
III. DOCUMENTS CONSIDERED TO BE RELEVANT® Category® Chaston of Document, 11 with indication, where appropriate, of the relevant passages 12 X GB, A, 820 014 (DAVENPORT) 16 September 1959 1-4 34- 38, see the whole document A US, A, 3 304 557 (POLANSKY) 21 February 1967 cited in the application A EP, A, 0 122 744 (HOWMEDICA) 24 October 1984 A WO, A, 8 303 752 (WALLSTEN) 10 November 1983 - WO, A, 8 303 752 (WALLSTEN) 10 November 1983 - US, A, 4 517 687 (MEADOX MEDICALS) 21 May 1985 cited in the application **Y document which may throw decision on priority claim(s) or which is cleated to stable the publication size of another the state of the arm of the publication size of another the state of the state of stable the publication size of another the state of another the state of the state of the state of another the state of the state of the state of another the state of the state of the state of another the state of the state of stable the publication size of another the state of the state of stable the state of another the state of the state of stable the state of another the state of the state of stable the st		station Searched	Minimum Docum		
Documentation Searched other than Miniaum Documentation to the Extent that such Documents are Included in the Fields Searched [®] EII. DOCUMENTS CONSIDERED TO BE RELEVANT [®] Category © Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹² X GB, A, 820 014 (DAVENPORT) 16 September 1959 1-4 34- 38, see the whole document A US, A, 3 304 557 (POLANSKY) 21 February 1967 cited in the application A EP, A, 0 122 744 (HOWMEDICA) 24 October 1984 WO, A, 8 303 752 (WALLSTEN) 10 November 1983 US, A, 4 517 687 (MEADOX MEDICALS) 21 May 1985 cited in thie application """ later document which may throw doubts on priority claim(s) or which is claim to the publication size of another claims of the considered to be of particular relevance." """ document which may throw doubts on priority claim(s) or which is claim to the publication due of another claims of the considered to involve an inventive step with the claim to the considered to involve an inventive step with the claim to be considered to involve an inventive step with the claim to be relevant the principly date claimed inventive step with the claim to principly claim claimed invention and the principly date claimed invention and the considered to involve an inventive step with the claim the principly date claimed invention and the considered to involve an inventive step with the claim the principly date claimed invention and the considered to involve an inventive step with the claim the principly date claimed invention and the considered to involve an inventive step with the claim the principly date claimed invention and the considered to involve an inventive step with the claim the principly date claimed invention and the considered to involve an inventive step with the claim the principly date claimed invention and the considered to involve an inventive step with the claimed invention and the considered to involve an inventive step with the claimed invention and the considered to involve an inventive step with the claimed i		lassification Symbols		etion System	Classificatio
III. DOCUMENTS CONSIDERED TO BE RELEVANT? Category Citation of Document, 11 with indication, where appropriate, of the relevant passages 12 Relevance of the whole document See the whole document A US, A, 3 304 557 (POLANSKY) 21 February 1967 Cited in the application A EP, A, 0 122 744 (HOWMEDICA) 24 October 1984 WO, A, 8 303 752 (WALLSTEN) 10 November 1983 US, A, 4 517 687 (MEADOX MEDICALS) 21 May 1985 Cited in the application Special categories of cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance; the claimed invention at Claimed Invention and Comment which may throw doubt on priority claim(s) or which is cited to scalability the publication extended to the considered to be of particular relevance; the claimed invention at Claimed Invention and Search Benefit of the same patient family "O" document referring to an oral disclosure, use, exhibition or document or claimed proof or cannot be considered moved on cannot be considered from the application of the international filling date but that the priority date claimed into a particular relevance; the claimed inventor as the work of			A61F	1. 5	Int.Cl.
Citation of Document, 11 with indication, where appropriate, of the relevant passages 12 Relevant (Comment of Document, 11 with indication, where appropriate, of the relevant passages 12 Relevant (Comment of Document, 11 with indication, where appropriate, of the relevant passages 12 Relevant (Comment of Document, 11 with indication, where appropriate, of the relevant passages 12 Relevant (Comment of Document, 11 with indication, where appropriate, of the relevant passages 12 Relevant (Comment of Document, 11 with indication, where appropriate, of the relevant passages 12 Relevant (Comment of Document, 11 with indication, where appropriate, of the relevant passages 12 Relevant (Comment of Document, 11 with indication of Document (Comment of Document, 12 step 1959) Relevant (Comment of Document, 11 with indication of Document of Document passages 12 Relevant (Comment passages 12	·	han Minimum Documentation re included in the Fields Searched ⁸	Documentation Searched other to the Extent that such Documents		
Citation of Document, 11 with Indication, where appropriate, of the relevant passages 12 X GB, A, 820 014 (DAVENPORT) 16 September 1959 1-4 34-38-38-38-38-38-38-38-38-38-38-38-38-38-			,		
GB, A, 820 014 (DAVENPORT) 16 September 1959 1-4 34- 38, see the whole document US, A, 3 304 557 (POLANSKY) 21 February 1967 cited in the application A EP, A, 0 122 744 (HOWMEDICA) 24 October 1984 A WO, A, 8 303 752 (WALLSTEN) 10 November 1983 A US, A, 4 517 687 (MEADOX MEDICALS) 21 May 1985 cited in the application "A" document defining the general state of the art which is not considered to be of particular relevance filling date "If document which may throw doubts on priority claims(s) or which is cited to establish the publication date of another citation or other special means (as periority date and not in conflict with the application of the special movement which may throw doubts on priority claims(s) or which is cited to establish the publication date of another citation or other special means (as periority claims(s) or which is cited to establish the publication date of another citation or other special means (as periority date and not in conflict with the application of the considered to involve an inventive step with constant or the priority date and not in conflict with the application of the same inventive and invention as inventive step with document which may be provide the considered to involve an inventive step with constant or particular relevance; the claimed involve an inventive step with constant or particular relevance; the claimed involve an inventive step with constant or particular relevance; the claimed involve an inventive step with constant or particular relevance; the claimed involve an inventive step with constant or particular relevance; the claimed involve an inventive step with constant or particular relevance; the claimed involve an inventive step with constant or particular relevance; the claimed involve an inventive step with constant or particular relevance; the claimed involve an inventive step with constant or particular relevance; the claimed involve an inventive step with constant or particular relevance; the calimed involve an inventive step with constant or parti	vant to Claim No.1				III. DOCUM
see the whole document US,A,3 304 557 (POLANSKY) 21 February 1967 cited in the application EP,A,0 122 744 (HOWMEDICA) 24 October 1984 WO,A,8 303 752 (WALLSTEN) 10 November 1983 US,A,4 517 687 (MEADOX MEDICALS) 21 May 1985 cited in the application "A" document defining the general state of the art which is not considered in be of particular relevances "E" earlier document but published on or after the international filling data "If document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specials) "O" document published prior to the international filling date but later than the priority date claimed lives cannot be considered in the conside	ART TO CIALIE ING.	te, of the relevant passages 12	cument, 11 with indication, where appropri	Citation of Do	Category °
US, A, 3 304 557 (POLANSKY) 21 February 1967 cited in the application EP, A, 0 122 744 (HOWMEDICA) 24 October 1984 WO, A, 8 303 752 (WALLSTEN) 10 November 1983 US, A, 4 517 687 (MEADOX MEDICALS) 21 May 1985 cited in the application "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "I" document which may throw doubt on priority clant(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, enhibition or other means "P" document published prior to the international filling date but later than the priority date claimed involve an inventive step involve an inventive step of the comment of general provides with one or more other such ments, such combination being obvious to a person in the art. "A" document referring to an oral disclosure, use, enhibition or other means. "P" document priority date claimed involve an inventive step involve an inventive step in the art. "A" document priority date claimed involve an inventive step in the art. "A" document priority date claimed involve an inventive step in the art. "A" document priority date claimed involve an inventive step in the priority date claimed involve an inventive step in the art. "A" document priority date claimed involve an inventive step in the art. "A" document priority date claimed involve an inventive step in the art. "A" document priority date claimed involve an inventive step in the art. "A" document priority date claimed involve an inventive step in the art. "A" document priority date claimed involve an inventive step in the art. "A" document priority date claimed involve an inventive step in the art. "A" document priority date claimed involve an inventive step in the art. "A" document priority date claimed inventive step in the art. "A" document member of the same patent family	4,6,8, -37, ,40,41	otember 1959	·		x
EP,A,O 122 744 (HOWMEDICA) 24 October 1984 WO,A,8 303 752 (WALLSTEN) 10 November 1983 US,A,4 517 687 (MEADOX MEDICALS) 21 May 1985 cited in the application "A" document defining the general state of the art which is not considered to be of particular relevance "E" examiner defining the general state of the art which is not considered to be of particular relevance; "If document which may throw doubts on priority claims(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed International Search Report W. CERTIFICATION Date of the Actual Completion of the International Search Date of Mailing of this International Search Report		ebruary 1967	 804 557 (POLANSKY) 21 F	US.A.3 3	A
"Special categories of cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "I." document which may throw doubts on priority claims(s) or which is cited to establish the publication date of another clistion or other special reason (as specified) "O" document referring to an oral disciosure, use, exhibition or other means "P" document published prior to the international filling date but later than the priority date claimed "V. CERTIFICATION Date of the Actual Completion of the International Search Date of Mailing of this International Search Report		October 1984		1	A
"T" later document published after the international filling date or priority date and not in conflict with the application or other special reason (as specified) "O" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disciosure, use, exhibition or other means "P" document published prior to the international filling date but later than the priority date claimed "X" document of particular relevance; the claimed inventor cannot be considered novel or cannot be considered involve an inventive step when the means is combined with one or more other such meant, such combination being obvious to a person in the art. "A" document of particular relevance; the claimed inventor cannot be considered involve an inventive step when the means is combined with one or more other such meants, such combination being obvious to a person in the art. "A" document of particular relevance; the claimed inventor cannot be considered in involve an inventive step when the meant is combined with one or more other such meants, such combination being obvious to a person in the art. "A" document of particular relevance; the claimed inventor cannot be considered involve an inventive step when the considered involve	•	ovember 1983	03 752 (WALLSTEN) 10 N	WO,A,8 3	A
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing data "I." document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, usa, exhibition or other neans "P" document published prior to the international filing date but later than the priority date claimed V. CERTIFICATION Date of the Actual Completion of the International Search Date of Mailing of this International Search Report		3) 21 May 1985			۹
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "I" document which may throw doubts on priority claims(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, usa, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search Date of Mailing of this International Search Report			•		
Date of the Actual Completion of the International Search Date of Mailing of this International Search Report	ation but ying the mitton of to mitton when the h docu-	or priority date and not in conflict with the a cited to understand the principle or theory un investion "X" document of particular relevance; the claimse cannot be considered novel or cannot be con- involve an inventive step "Y" document of particular relevance; the claimse cannot be considered to involve an inventive document is combined with one or more othe ments, such combination being obvious to a in the art.	eral state of the art which is not iar relevance shed on or after the international values on priority claims(s) or the publication date of another ason (as specified) wal disclosure, use, exhibition or the international filling date but	cament defining the generalised to be of particular occurrent but publishing data cament which may throw the is cited to establish the ation or other special rescurrent referring to an other means cament published prior to	"A" docum consist filing "L" docum which citatio "O" docum other "P" docum
Date of the Action Compression of the Compression o					
· · · · · · · · · · · · · · · · · · ·		Date of Mailing of this International Search			Date of the Ac
International Searching Authority EUROPEAN PATENT OFFICE Signature of Authorized Officer STEENBAKKER J.	M	_			aternational S

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. US 9105907 SA 50854

This amex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 02/01/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A-820014		None	
US-A-3304557		None	
EP-A-0122744	24-10-84	US-A- 4610688 AU-B- 554461 AU-A- 2636584 CA-A- 1220601 JP-C- 1375239 JP-A- 59194738 JP-B- 61040420 US-A- 4834755	09-09-86 21-08-86 11-10-84 21-04-87 22-04-87 05-11-84 09-09-86 30-05-89
WO-A-8303752	10-11-83	SE-B- 445884 AU-A- 1518683 CA-A- 1239755 CH-A- 662051 DE-T- 3342798 FR-A- 2525896 GB-A,B 2135585 JP-T- 59500652 NL-T- 8320142 SE-A- 8202739 US-A- 4954126 US-A- 4655771	28-07-86 21-11-83 02-08-88 15-09-87 10-01-85 04-11-83 05-09-84 19-04-84 01-08-84 31-10-83 04-09-90 07-04-87
US-A-4517687 	21-05-85	CA-A- 1215896 DE-A- 3278417 EP-A,B 0108171 JP-A- 59049757	30-12-86 09-06-88 16-05-84 22-03-84
		ropean Patent Office, No. 12/82	